Oxford Biomedica's H1 Revenue Jumps; FY26 Outlook Updated

MT Newswires · 2d ago
02:53 AM EDT, 08/07/2026 (MT Newswires) -- Oxford Biomedica (OXB.L) said Friday its revenue grew 9% year over year for the six months ended June 30 to 80 million pounds sterling. For 2026, the cell and gene therapy company now forecasts revenue of between 180 million pounds and 200 million pounds, against the previous forecast of 220 million pounds to 240 million pounds. Looking further ahead, the company maintained its target of 25% to 30% revenue growth for 2027.